Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements of the results of clinical studies, the timing of clinical trials and development efforts and the timing of closing the proposed merger are all forward-looking statements. The potential risks and uncertainties include, among others, that clinical results will not be maintained in final data analysis, that current or future clinical trials will not be successful or confirm the results of earlier studies, risks related to the timing and costs of clinical trials and regulatory approvals, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the possibility that the merger with Sonus does not close or that the closing may be delayed. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of OncoGenex. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

Proxy Solicitation

In connection with the proposed merger, Sonus filed with the SEC a Proxy Statement and related materials on July 3, 2008 containing information about Sonus, OncoGenex and the proposed merger. Sonus mailed the Proxy Statement to its stockholders on or about July 9, 2008. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND THE OTHER RELEVANT MATERIALS, CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT SONUS, ONCOGENEX AND THE PROPOSED MERGER.

Sonus and OncoGenex, and certain of their directors, executive offi
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... N.J. , June 1, 2015  The Val ... a national innovative science curriculum for high school students ... the 16 th annual LIFE Event (LPGA Pros ... Mountain Ridge Country Club in West Caldwell, ... the LPGA,s biggest stars raised more than $500,000 on ...
(Date:6/1/2015)... , June 1, 2015  Neogen Corporation (NASDAQ: NEOG ... Sterling Test House, a leading commercial food testing laboratory based ... acquired laboratory will serve as a base for the company,s ... Sterling Test House was incorporated in 1990, ... the food safety and water quality testing for major hotels ...
(Date:6/1/2015)... --  Epic Sciences, Inc. , a private diagnostics company ... and advance the treatment and management of cancer, announced ... its existing credit facility with Silicon Valley Bank ... of the facility from $5 million to $15 million ... April 1, 2019.  The availability of additional capital provides ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Strategies in the US ... their offering. This new 373-page ... comprehensive analysis of the POC clinical chemistry ... requirements, technological trends, competitive landscape, and emerging ...
Breaking Biology Technology:Val Skinner Foundation Announces Partnership With Discovery Education 2Neogen acquires India food safety company 2Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... July 30 /PRNewswire-Asia/ -- Eli Lilly & Company ... they have,reached an amicable resolution of all ongoing ... and sale of gemcitabine,hydrochloride around the world. , ... settlement, Lilly has granted ScinoPharm a royalty bearing,license ...
... TOKYO, July 30 With a ... Pharmaceutical Co. Ltd., a subsidiary of,the Zydus group, one of ... looking to give a big boost to its operations,in the ... market in Japan is estimated at $ 60 bn the ...
... viable solar power cellscheap, flexible and easy to makehas ... of recent work* at the National Institute of Standards ... of the complex organic films at the heart of ... molecules to capture sunlight and convert it into electricity, ...
Cached Biology Technology:Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation 2"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila 2NIST scientists study how to stack the deck for organic solar power 2
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Researchers presented Phase III efficacy data from the GeparQuinto ... in combination with chemotherapy for patients with early breast ... Cancer Symposium, held Dec. 8-12. "We had ... combination of chemotherapy, trastuzumab, with the new combination of ...
... the World Health Organization Collaborating Centre for Metabolic Bone Diseases ... a FRAX calculator for Singapore. The FRAX tool ... by the WHO to help evaluate patients at low, medium ... factors, with or without the use of bone mineral density ...
... in recent years to reduce carbon emissions by increasing efficiency ... carbon emissions in China have grown dramatically during that same ... questions about who is to blame when the coal China ... are produced to manufacture goods exported back to places with ...
Cached Biology News:Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer 2WHO Fracture Risk Assessment Tool (FRAX) newly released for Singapore 2
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... of the COP9 signalosome complex (CSN), a ... processes. The CSN complex is an essential ... by mediating the deneddylation of the cullin ... complex is also involved in phosphorylation of ...
... 96 well Magnetic-Ring Stand is designed for ... U-bottom microplates. The stand has a plastic ... microtiter plate footprint. The use of 96 ... and easy magnetic separation. With this magnetic ...
6B9...
Biology Products: